CN1665511A - 促使吸烟者戒烟的方法 - Google Patents

促使吸烟者戒烟的方法 Download PDF

Info

Publication number
CN1665511A
CN1665511A CN038156369A CN03815636A CN1665511A CN 1665511 A CN1665511 A CN 1665511A CN 038156369 A CN038156369 A CN 038156369A CN 03815636 A CN03815636 A CN 03815636A CN 1665511 A CN1665511 A CN 1665511A
Authority
CN
China
Prior art keywords
purposes
reboxetine
smoking
officinal salt
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN038156369A
Other languages
English (en)
Chinese (zh)
Inventor
E·H·F·旺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of CN1665511A publication Critical patent/CN1665511A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN038156369A 2002-07-01 2003-06-26 促使吸烟者戒烟的方法 Pending CN1665511A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39289302P 2002-07-01 2002-07-01
US60/392,893 2002-07-01

Publications (1)

Publication Number Publication Date
CN1665511A true CN1665511A (zh) 2005-09-07

Family

ID=30000949

Family Applications (1)

Application Number Title Priority Date Filing Date
CN038156369A Pending CN1665511A (zh) 2002-07-01 2003-06-26 促使吸烟者戒烟的方法

Country Status (22)

Country Link
US (1) US20040102440A1 (sr)
EP (1) EP1534254A2 (sr)
JP (1) JP2005531631A (sr)
CN (1) CN1665511A (sr)
AP (1) AP2004003188A0 (sr)
AU (1) AU2003253609A1 (sr)
BR (1) BR0312293A (sr)
CA (1) CA2491549A1 (sr)
EA (1) EA200401584A1 (sr)
EC (1) ECSP045517A (sr)
HR (1) HRP20041194A2 (sr)
IL (1) IL165882A0 (sr)
IS (1) IS7600A (sr)
MA (1) MA27597A1 (sr)
MX (1) MXPA05000296A (sr)
NO (1) NO20045535L (sr)
OA (1) OA12878A (sr)
PL (1) PL373620A1 (sr)
RS (1) RS115204A (sr)
TN (1) TNSN04267A1 (sr)
WO (1) WO2004002463A2 (sr)
ZA (1) ZA200410339B (sr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102573821A (zh) * 2009-09-30 2012-07-11 哈兰·克莱顿·比利 保持体重的戒烟法及营养补充剂
CN104381577A (zh) * 2014-11-18 2015-03-04 安徽润康保健食品有限公司 一种具有戒烟功能的口香糖

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
DK1803443T3 (en) 2002-12-20 2019-02-25 Niconovum Ab Nicotine-containing particulate material with a crystalline cellulose
WO2004096201A1 (en) 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
EP1870096A3 (en) * 2003-04-29 2011-04-20 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
RU2408368C2 (ru) 2005-06-27 2011-01-10 Биовэйл Лэборэториз Интернэшнл С.Р.Л. Препараты соли бупропиона с модифицированным высвобождением
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
CA2646942C (en) 2006-03-16 2014-07-29 Modoral Brands Inc. Improved snuff composition
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US20070297991A1 (en) * 2006-06-23 2007-12-27 Minu, L.L.C. Neural conduit agent dissemination for smoking cessation and other applications
KR20150082689A (ko) 2006-11-09 2015-07-15 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
EP2170274A1 (en) * 2007-07-02 2010-04-07 Technion Research and Development Foundation, Ltd. Compositions, articles and methods comprising tspo ligands for preventing or reducing tobacco-associated damage
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US20110046116A1 (en) * 2009-08-20 2011-02-24 Cukrowski Walter J Sedative for use during eye surgery
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
HRP20191305T1 (hr) 2010-07-09 2019-10-18 Bioverativ Therapeutics Inc. Preradive jednolančane molekule i polipeptidi izrađeni koristeći iste
HUE072188T2 (hu) 2012-06-06 2025-10-28 Nalpropion Pharmaceuticals Llc Készítmény magas kardiovaszkuláris kockázatú túlsúlyos és elhízott páciensek kezelésére szolgáló eljárásban történõ alkalmazásra
AU2014336959A1 (en) * 2013-10-14 2016-05-26 Palmaya Pty Ltd Compositions and methods of administering same
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
EP3082816B1 (en) 2013-12-20 2019-03-20 Indivior UK Limited Intranasal naloxone compositions and methods of making and using same
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
EP3923919A4 (en) 2019-02-17 2022-12-07 Neurawell Therapeutics COMPOSITIONS AND METHODS FOR TREATMENT OF DEPRESSION AND OTHER DISEASES
US12616702B2 (en) 2019-12-03 2026-05-05 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
WO2021158957A1 (en) 2020-02-05 2021-08-12 Summit Biosciences Inc. Drug products for intranasal administration and uses thereof
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion
US12565478B1 (en) 2025-01-21 2026-03-03 Axsome Therapeutics, Inc. (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1069900B1 (en) * 1998-04-09 2005-08-10 Pharmacia & Upjohn Company LLC Use of reboxetine for the treatment of neuropsychiatric disorders
PT1075264E (pt) * 1998-05-08 2005-01-31 Upjohn Co Novas combinacoes farmacologicas de reboxetina e pindolol
ES2246488T3 (es) * 1999-07-01 2006-02-16 PHARMACIA & UPJOHN COMPANY LLC Reboxetina para tratar la migraña.
DE10004547A1 (de) * 2000-02-02 2001-08-09 Liedtke Pharmed Gmbh Verfahren zur selektiven Verabreichung zentralnervös aktiver Stoffe

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102573821A (zh) * 2009-09-30 2012-07-11 哈兰·克莱顿·比利 保持体重的戒烟法及营养补充剂
CN104381577A (zh) * 2014-11-18 2015-03-04 安徽润康保健食品有限公司 一种具有戒烟功能的口香糖

Also Published As

Publication number Publication date
AP2004003188A0 (en) 2004-12-31
HRP20041194A2 (en) 2005-06-30
ZA200410339B (en) 2006-07-26
WO2004002463A3 (en) 2004-02-19
IS7600A (is) 2004-12-16
EA200401584A1 (ru) 2005-08-25
OA12878A (en) 2006-09-15
JP2005531631A (ja) 2005-10-20
NO20045535L (no) 2005-01-27
RS115204A (sr) 2007-02-05
WO2004002463A2 (en) 2004-01-08
PL373620A1 (en) 2005-09-05
CA2491549A1 (en) 2004-01-08
AU2003253609A1 (en) 2004-01-19
ECSP045517A (es) 2005-03-10
MXPA05000296A (es) 2005-08-19
IL165882A0 (en) 2006-01-15
MA27597A1 (fr) 2005-11-01
BR0312293A (pt) 2005-04-12
US20040102440A1 (en) 2004-05-27
TNSN04267A1 (fr) 2007-03-12
EP1534254A2 (en) 2005-06-01

Similar Documents

Publication Publication Date Title
CN1155410C (zh) 治疗尼古丁成瘾的含有尼古丁受体拮抗剂和抗抑郁药或抗焦虑药的组合物
US20040102440A1 (en) Method of promoting smoking cessation
CA2548917C (en) Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
EP1107746B1 (en) Methods of using and compositions comprising dopamine reuptake inhibitors
CN1368878A (zh) 用于治疗腿不宁综合症的药物
JP2000508341A (ja) 片頭痛の治療法及び薬効の強化組成物
JP2009517393A (ja) 不安症の治療方法
CN1527711A (zh) 用于药物治疗成瘾性物质或麻醉剂成瘾的活性成分组合物
KR20210095734A (ko) 신경정신계 장애의 치료를 위한 조성물 및 방법
MX2008015887A (es) Tratamiento de condiciones psicologicas utilizando antagonista m1 de receptor muscarinico.
WO1999061014A2 (en) Compositions and methods employing r(-) fluoxetine and other active ingredients
US20040115263A1 (en) Use of bupropion for treating restless legs syndrome
HK1076736A (en) Method of promoting smoking cessation
CA2338326A1 (en) Use of moclobemide and metabolites for treating and preventing substance abuse
KR20050016679A (ko) 금연을 촉진시키는 방법
HUP0401013A2 (hu) Hatóanyag-kombináció nikotinfüggőség gyógyszeres kezelésére és ezt tartalmazó gyógyszerkészítmény
JP2007528891A (ja) 複合鎮痛剤医薬組成物
HK1034662B (en) Composition for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug
HUP0202290A2 (hu) Fájdalomcsillapító hatású kombinációs gyógyászati készítmény

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1076736

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1076736

Country of ref document: HK